Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).

BMC Surg 2008 Aug 22;8:15. Epub 2008 Aug 22.

Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.

Background: With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction. The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs.

Methods/design: The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007.

Discussion: The LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.

Trial Registration: Nederlands Trial Register NTR1150.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2482-8-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533646PMC
August 2008
88 Reads

Publication Analysis

Top Keywords

crohn's disease
20
laparoscopic ileocolic
16
ileocolic resection
16
infliximab treatment
16
recurrent crohn's
12
disease
9
treatment
9
inflammatory bowel
8
bowel disease
8
quality life
8
will calculated
8
patients will
8
ileitis crohn's
8
multicenter trial
8
randomized multicenter
8
infliximab
8
distal ileitis
8
patients
6
crohn's
6
will
6

References

(Supplied by CrossRef)

SB Hanauer et al.
Inflamm Bowel Dis 2006

F Baert et al.
N Engl J Med 2003

P Rutgeerts et al.
Gastroenterology 2004

SP Travis et al.
Gut 2006

EF Stange et al.
Gut 2006

EJ Eshuis et al.
2008

JK Lowney et al.
Dis Colon Rectum 2006

T Bernklev et al.
Eur J Gastroenterol Hepatol 2005

JR Love et al.
J Clin Gastroenterol 1992

CP Delaney et al.
J Am Coll Surg 2003

HJ Duepree et al.
Dis Colon Rectum 2002

Similar Publications